| Host: |
Rabbit |
| Applications: |
WB/ELISA |
| Reactivity: |
Human/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-LIM domain-binding protein 3 (41-90 aa) is suitable for use in Western Blot and ELISA research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-2000ELISA 1:5000-20000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
LDB3 |
| Gene ID: |
11155 |
| Uniprot ID: |
LDB3_HUMAN |
| Immunogen Region: |
41-90 aa |
| Specificity: |
LDB3 Polyclonal Antibody detects endogenous levels of protein. |
| Immunogen: |
Synthesized peptide derived from the human protein at the amino acid range 41-90 |
| Function | May function as an adapter in striated muscle to couple protein kinase C-mediated signaling via its LIM domains to the cytoskeleton. |
| Protein Name | Lim Domain-Binding Protein 3Protein CypherZ-Band Alternatively Spliced Pdz-Motif Protein |
| Cellular Localisation | CytoplasmPerinuclear RegionCell ProjectionPseudopodiumCytoskeletonMyofibrilSarcomereZ LineLocalized To The Cytoplasm Around Nuclei And Pseudopodia Of Undifferentiated Cells And Detected Throughout The Myotubes Of Differentiated CellsColocalizes With Actn2 At The Z-Lines |
| Alternative Antibody Names | Anti-Lim Domain-Binding Protein 3 antibodyAnti-Protein Cypher antibodyAnti-Z-Band Alternatively Spliced Pdz-Motif Protein antibodyAnti-LDB3 antibodyAnti-KIAA0613 antibodyAnti-ZASP antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
